<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>5</volume><submitter>Javed M</submitter><pubmed_abstract>&lt;h4>Introduction&lt;/h4>Early kidney transplant failure has significant negative impact for individuals and healthcare systems. Contemporary data investigating early allograft failure are lacking. We undertook a retrospective observational cohort study of adult patients who underwent kidney transplantation at a single European centre.&lt;h4>Methods&lt;/h4>We determined causes of allograft failure between 1 and 5 years after transplant and explored clinical variables present at 1 year that predicted allograft loss.&lt;h4>Results&lt;/h4>591 patients (median age 50 years, 64.1% male, and 44% white) were included; 531 (89.8%) had graft survival and 60 (10.2%) had graft loss between 1- and 5-years. Rejection was the primary cause of graft failure in 24 (40%) cases and 54% had undetectable tacrolimus levels prior to failure event. Female sex, serum creatinine at 1 year, the occurrence of rejection, and undetectable tacrolimus levels were associated with increased odds of graft loss. In subsequent analysis of 787 patients alive with a functioning graft at 1 year, recipient age, serum creatinine, proteinuria, any rejection episode, and tacrolimus intrapatient variability (IPV) at 1 yearwere associated with an increased hazard of graft loss.&lt;h4>Discussion&lt;/h4>Hence, graft losses were predominantly alloimmune mediated, often associated with non-adherence, and were predicted by tacrolimus IPV at 1 year.</pubmed_abstract><journal>Frontiers in nephrology</journal><pagination>1666191</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12740892</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Tacrolimus intrapatient variability and rejection are associated with inferior allograft outcomes after kidney transplantation.</pubmed_title><pmcid>PMC12740892</pmcid><pubmed_authors>Khan AA</pubmed_authors><pubmed_authors>Evans RDR</pubmed_authors><pubmed_authors>Sanghera A</pubmed_authors><pubmed_authors>Needleman A</pubmed_authors><pubmed_authors>Javed M</pubmed_authors><pubmed_authors>Nagpal R</pubmed_authors><pubmed_authors>Jones G</pubmed_authors><pubmed_authors>Harber M</pubmed_authors><pubmed_authors>Fernando R</pubmed_authors><pubmed_authors>Hobill A</pubmed_authors><pubmed_authors>Thal N</pubmed_authors><pubmed_authors>Gage A</pubmed_authors><pubmed_authors>Karst F</pubmed_authors><pubmed_authors>Hmun M</pubmed_authors><pubmed_authors>Butler K</pubmed_authors><pubmed_authors>Shirling G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Tacrolimus intrapatient variability and rejection are associated with inferior allograft outcomes after kidney transplantation.</name><description>&lt;h4>Introduction&lt;/h4>Early kidney transplant failure has significant negative impact for individuals and healthcare systems. Contemporary data investigating early allograft failure are lacking. We undertook a retrospective observational cohort study of adult patients who underwent kidney transplantation at a single European centre.&lt;h4>Methods&lt;/h4>We determined causes of allograft failure between 1 and 5 years after transplant and explored clinical variables present at 1 year that predicted allograft loss.&lt;h4>Results&lt;/h4>591 patients (median age 50 years, 64.1% male, and 44% white) were included; 531 (89.8%) had graft survival and 60 (10.2%) had graft loss between 1- and 5-years. Rejection was the primary cause of graft failure in 24 (40%) cases and 54% had undetectable tacrolimus levels prior to failure event. Female sex, serum creatinine at 1 year, the occurrence of rejection, and undetectable tacrolimus levels were associated with increased odds of graft loss. In subsequent analysis of 787 patients alive with a functioning graft at 1 year, recipient age, serum creatinine, proteinuria, any rejection episode, and tacrolimus intrapatient variability (IPV) at 1 yearwere associated with an increased hazard of graft loss.&lt;h4>Discussion&lt;/h4>Hence, graft losses were predominantly alloimmune mediated, often associated with non-adherence, and were predicted by tacrolimus IPV at 1 year.</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025</publication><modification>2026-06-06T05:46:44.247Z</modification><creation>2026-05-26T03:12:22.737Z</creation></dates><accession>S-EPMC12740892</accession><cross_references><pubmed>41458304</pubmed><doi>10.3389/fneph.2025.1666191</doi></cross_references></HashMap>